CAP Bages
Manresa, Barcelona, 08242, Spain
NCT Number: NCT04132401
Background: Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries. In diabetic patients, periodic examination of the back of the eye using a nonmydriatic camera has been widely demonstrated to be an effective system to control and prevent the onset of DR. Convolutional neural networks have been used to detect DR, achieving very high sensitivities and specificities.
Hypothesis: It is possible to develop algorithms based on artificial intelligence that can demonstrate equal or superior performance and that constitute an alternative to the current screening of DR and other ophthalmic pathologies in diabetic patients.
Objectives:
* Development of an artificial intelligence system for the detection of signs of retinal pathology and other ophthalmic pathologies in diabetic patients. * Scientific validation of the system to be used as a screening system in primary care.
Methods: This project consisted of carrying out two studies simultaneously:
1. Development of an algorithm with artificial intelligence to detect signs of DR and other pathologies of the central retina in patients with diabetes. 2. An observational, cross-sectional study comparing the diagnostic capacity of the algorithms with that of the family medicine specialists who read the fundus images. The reference was double-blind reading by ophthalmologists who specialize in retina.
The cession of the images began at the end of 2018. The images used for the validation were obtained during routine diabetic retinopathy screening between May and August 2021. The results have since been published.
The study allowed the development of an algorithm based on AI able to demonstrate an equal or superior performance, and to constitute a complement or an alternative to the current screening of DR in diabetic patients.
Looking for future studies?
Notify MeAll sexes
Observational
Manresa, Barcelona, 08242, Spain
Study Design This project followed a methodology consisting of 2 concomitant studies: In the first study, an AI algorithm was developed to detect the signs of DR in patients with diabetes. The second part of the project consisted of an observational, cross-sectional study comparing the diagnostic capacity of the algorithm with that of the family medicine physicians and with retina specialists. The reference was a blinded double reading conducted by the retina specialists (with a blinded third reading in case of disagreement in the previous 2 readings). In this way, the results obtained, both by the AI algorithm and by family medicine specialists, were compared using the gold standard (accuracy, sensitivity, specificity, area under the curve, retina specialists (with a blinded third reading in case of disagreement in the previous 2 readings). In this way, the results obtained, both by the AI algorithm and by family medicine specialists, were compared using the gold standard (accuracy, sensitivity, specificity, area under the curve, etc). The inclusion of nurses who received training in fundus readings was considered to compare their diagnostic capacity.
Study Population, Site Participation, and Recruitment. Images for the development of the algorithm were ceded by the CHS and included images from the whole Catalan population. The study took place in the primary care centers managed by the Catalan Health Institute in Central Catalonia, which includes the counties of Bages, Osona, Berguedà, and Anoia. The reference population was the population assigned to these primary care centers. This population included about 512,000 people in 2017, with an estimated prevalence of diabetes of 7.1%. The study period included 2010-2017 for the development of the algorithm with AI. Once the algorithm had been developed, the study was conducted on fundus images obtained during routine diabetic retinopathy screening over a period of about 3-4 months, between May and August 2021.
Conduct of the Study. For the development of the AI algorithm, all fundus images labeled as DR of patients from primary care centers in Catalonia between 2010 and 2017 were included. For the study, all the images of patients who underwent an eye fundus examination were included until the adequate number of patients was reached. A high percentage of the fundus images had sufficient quality; that is, a 40-degree vision of the central retina where at least a three-fourth part of the optic nerve, a well-focused macula, and well-defined veins and arteries of the upper and lower arcs can be seen. Eye fundus images that did not have adequate technical quality (dark) or that could not be evaluated due to the opacity of the media (eg, for cataracts) were excluded.
Data Collection. For the development of the AI algorithm, anonymized images with the corresponding label that classifies each image (in one of the classes with which the algorithm was trained) were required. The personnel responsible for information technology (IT) of the CHS evaluated the best strategy for the anonymization and extraction of the images from the computer systems of the CHS, as well as the identification of each image with a unique identifier. A tabulated file type CSV or TXT was used to relate each image identifier with the corresponding classification. The person responsible for IT of the CHS, together with the technical manager of OPTretina, agreed on the best way to transfer these 2 sources of information, in a secure way, from the CHS servers to the OPTretina servers (SSH File Transfer Protocol, external hard disk), depending on the volume of data to be transferred and the internal policy of the CHS. OPTretina is experienced in developing AI models for automatic fundus image classification and is a Spanish Agency of Medicines and Health Products-certified medical device manufacturer. For the study, anonymized weekly fundus readings collected by family medicine physician readers of fundus images in Central Catalonia were collected. The images were transferred to the OPTretina servers to be first analyzed by the diagnostic algorithm and then by the retina specialists who made the definitive diagnosis. The person responsible for IT of the CHS, together with the technical manager of OPTretina, agreed on the best way to transfer these data in a secure manner.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
Time frame: 1 year
True positive rate of the algorithm
Time frame: 1 year
True negative rate of the algorithm
Time frame: 1 year
Ratio of number of correct predictions to the total number of input samples
Time frame: 1 year
Diagnostic ability of the algorithm
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Other
Artificial Intelligence for the Detection of Central Retinal Disease and Non-mydriatic Glaucoma in the Context of Patients With Diabetes Mellitus in Primary Care: A Prospective Study Comparing the Diagnostic Capacity of an AI Algorithm
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06213896
Age-Related Macular Degeneration, Cardiovascular Diseases
Antalya, Turkey (Türkiye)
View Trial DetailsNCT05135195
Age-Related Macular Degeneration, Cardiovascular Diseases
New York, United States
View Trial DetailsNCT00556114
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion
Irvine, California, United States
View Trial DetailsNCT01692938
Age-Related Macular Degeneration, Cardiovascular Diseases
Fort Lauderdale, Florida, United States
View Trial Details